An interdisciplinary research team from Leipzig University and the Saxon AI center ScaDS.AI has developed a novel approach ...
The year 2015 marked the inception of Sanyou Bio's technological journey, laying the foundation for its core technology platform. The R&D team devoted itself to the development of display vectors, ...
Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.
The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery ...
15don MSN
You enjoy reading prose laden with immersive descriptionsStarward Vector has plenty of words and minutiae, accompanied by some portraits and an astounding map design. The bulk of the action is ...
Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...
VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S.
We reviewed the best free Adobe Illustrator alternatives for managing graphics files without a Creative Cloud subscription. We've rounded-up our top-rated choices for when you want to make the ...
Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...
C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...
Last northern autumn, Nvidia open sourced its BioNeMo family of GPU-accelerated machine learning frameworks for drug development and molecular design. The company has also taken steps to repackage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results